TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8876886

Group type: EXPERIMENTAL
Intervention: 2-cm margin
Number of subjects: 742

Group type: COMPARATOR
Intervention: 4-cm margin
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Thickness of primary lesion
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Ulceration of primary lesion
Number of subjects: 742
Study: 2062330

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 102

Group type: COMPARATOR
Intervention: Plasma infusion
Number of subjects: 102
Study: 6192139

Group type: EXPERIMENTAL
Intervention: High dosage regimen (group A) - MMI: 60 +/- 14.5 mg/day or PTU: 693 +/- 173 mg/day, with T3 addition.
Number of subjects: 113

Group type: COMPARATOR
Intervention: Low dosage regimen (group B) - MMI: 13.6 +/- 7 mg/day or PTU: 180 +/- 58 mg/day, without T3 addition.
Number of subjects: 113
Study: 30624373

Group type: EXPERIMENTAL
Intervention: Pursed Lip Breathing (PLB)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual breathing
Number of subjects: 35
Study: 28760461

Group type: EXPERIMENTAL
Intervention: Added dead space (aDS) during mild exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mild exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no added dead space)
Number of subjects: 10
Study: 24866854

Group type: EXPERIMENTAL
Intervention: Acceptance Facilitating Intervention (short informational video)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No-intervention Control Group (CG)
Number of subjects: 104
Study: 24075228

Group type: EXPERIMENTAL
Intervention: Cultured allogeneic fibroblasts in a crystalloid suspension solution with 2% albumin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suspension solution alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (fibroblasts and suspension solution)
Number of subjects: 0
Study: 21666590

Group type: EXPERIMENTAL
Intervention: Nakom (levodopa and carbidopa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tidomed (levodopa and carbidopa)
Number of subjects: 0
Study: 19571078

Group type: EXPERIMENTAL
Intervention: Locked volar plate
Number of subjects: 46

Group type: COMPARATOR
Intervention: Augmented external fixation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Locked radial column plate
Number of subjects: 46
Study: 16863598

Group type: EXPERIMENTAL
Intervention: Cognitive functioning assessed 6 weeks after surgery
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Fear of falling assessed 6 weeks after surgery
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Pain assessed within 2 weeks after surgery
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed within 2 weeks after surgery
Number of subjects: 291
Study: 14769578

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 34

Group type: COMPARATOR
Intervention: Subarachnoid block
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 34
Study: 11840725

Group type: EXPERIMENTAL
Intervention: Clinical practice guidelines (CPGs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines that passed the appraisal process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines for guideline development by the Scottish Intercollegiate Guideline Network
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 9491016

Group type: EXPERIMENTAL
Intervention: Gimme‐5 program with teacher wellness program (54 workshops over 2 years)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gimme‐5 program (comparison group)
Number of subjects: 32
Study: 8153578

Group type: EXPERIMENTAL
Intervention: Triclosan in polyethylene glycol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triclosan in glycerol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triclosan in 3% sodium lauryl sulfate (SLS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triclosan in Tween 80
Number of subjects: 8
Study: 2971565

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium bromide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Perfusion of aminophylline
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of bronchodilators
Number of subjects: 13
Study: 31622386

Group type: EXPERIMENTAL
Intervention: Computerized Speed of Processing Training (SOPT)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Computerized crossword puzzles (control)
Number of subjects: 351
Study: 29171497

Group type: EXPERIMENTAL
Intervention: mCIMT
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: touch glove
Number of subjects: 88

Group type: COMPARATOR
Intervention: control group
Number of subjects: 88
Study: 26218883

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - myofascial induction technique added to a multimodal protocol including neuromuscular technique over the masseter muscles and passive hamstring muscle stretching.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (CG) - neuromuscular technique over the masseter muscles and passive hamstring muscle stretching.
Number of subjects: 60
Study: 23403474

Group type: EXPERIMENTAL
Intervention: Oral citicoline 500 mg twice a day
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 349
Study: 22122817

Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg and HCT 25 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Candesartan 32 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: HCT 25 mg
Number of subjects: 53
Study: 19593887

Group type: EXPERIMENTAL
Intervention: Intraarticular + subacromial injection
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intraarticular injection
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Subacromial injection
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Interscalenic brachial plexus block (IBPB)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 17047178

Group type: EXPERIMENTAL
Intervention: Nutrison Pack (1-L enteral feeding system)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Glass bottle system (0.5-L)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Delivery sets
Number of subjects: 207
Study: 12923727

Group type: EXPERIMENTAL
Intervention: Angiotensin antagonists, lifestyle changes, and appropriate drugs to reduce cardiovascular risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapies (corticosteroids, cyclosporine, mycophenolate, cyclophosphamide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 10839912

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous low-dose ketamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of epidural morphine and intravenous ketamine
Number of subjects: 0
Study: 9282292

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUV-P)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TUR-P)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUV-P) (roller bar)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUV-P) (roller loop)
Number of subjects: 27
Study: 8359644

Group type: EXPERIMENTAL
Intervention: 2% oleic acid
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 20% oleic acid
Number of subjects: 7

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 7
Study: 3730737

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: No specific therapy (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (treated and control)
Number of subjects: 40
Study: 30866027

Group type: EXPERIMENTAL
Intervention: Nutritional counseling and medical therapy (treated)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Routine pregnancy management (untreated)
Number of subjects: 457
Study: 29678193

Group type: EXPERIMENTAL
Intervention: Prolonged grief-specific integrative cognitive behavioral therapy (PG-CBT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Present-centered therapy (PCT)
Number of subjects: 204
Study: 27174250

Group type: EXPERIMENTAL
Intervention: Health mindset
Number of subjects: 60

Group type: COMPARATOR
Intervention: Palatability mindset
Number of subjects: 60
Study: 24956865

Group type: EXPERIMENTAL
Intervention: Pingshen decoction 1 dose/d, bid po for 8 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: NephritisShu tablet, 6 tablets, tid po for 8 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Healthy control group (30 cases)
Number of subjects: 69
Study: 23356030

Group type: EXPERIMENTAL
Intervention: Single dose rifampicin (SDR) chemoprophylaxis
Number of subjects: 28092

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 28092
Study: 21269040

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan, 2.0% PVM/MA copolymer, 0.243% sodium fluoride dentifrice
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride, sodium hexametaphosphate, zinc lactate dentifrice
Number of subjects: 182

Group type: COMPARATOR
Intervention: 0.243% sodium fluoride dentifrice
Number of subjects: 182
Study: 19011427

Group type: EXPERIMENTAL
Intervention: Olanzapine (20 mg/d)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/d, increasing to 30 mg/d as needed)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Control (Lorazepam as needed, total dose ≤ 4 mg/d)
Number of subjects: 604
Study: 16151977

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (0.3 U/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Insulin lispro (0.3 U/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Regular human insulin (0.3 U/kg)
Number of subjects: 18
Study: 12823705

Group type: EXPERIMENTAL
Intervention: Super‐EBA
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: ProRoot‐MTA
Number of subjects: 81

Group type: COMPARATOR
Intervention: Finishing bur
Number of subjects: 81

Group type: COMPARATOR
Intervention: Ball burnishing or Zekrya bur
Number of subjects: 81
Study: 10999651

Group type: EXPERIMENTAL
Intervention: Salbutamol 8 mg [β‐2]
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg [mainly β‐2]
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Xamoterol 200 mg [β‐1]
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 8604657

Group type: EXPERIMENTAL
Intervention: High-ketogenic VLED
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low-ketogenic VLED
Number of subjects: 13
Study: 8136625

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (1 unit/ml) added to pre-mixed fluids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fluids (control group)
Number of subjects: 0
Study: 3304022

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CV)
Number of subjects: 7
Study: 29660858

Group type: EXPERIMENTAL
Intervention: Peer counselling from trained community female volunteers starting in third trimester of pregnancy until 6 months after delivery
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 350
Study: 26906014

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg before surgery, 40 mg morning of surgery, 40 mg daily after surgery)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg morning of surgery, 40 mg morning after)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study: 26502545

Group type: EXPERIMENTAL
Intervention: Red-hot needle therapy, treated with cauterized needles on specific acupuncture points, once every other day for 30 days.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine acupuncture, treated with filiform needles on specific acupuncture points, once daily for 30 days.
Number of subjects: 80
Study: 23885607

Group type: EXPERIMENTAL
Intervention: Acupuncture (electroacupuncture at Zusanli, Sanyinjiao, and Taichong for 30 min, once a day for 2 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Motilium (10 mg orally, three times a day for 2 weeks)
Number of subjects: 40
Study: 20665738

Group type: EXPERIMENTAL
Intervention: Possible arthritis (chronic joint symptoms without doctor‐diagnosed arthritis)
Number of subjects: 2884
Study: 18455211

Group type: EXPERIMENTAL
Intervention: AZD4619
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenofibric acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPAR agonists
Number of subjects: 0
Study: 17012045

Group type: EXPERIMENTAL
Intervention: Prognostic index scoring based on age, sex, performance status, histological type, and TNM staging.
Number of subjects: 4479

Group type: EXPERIMENTAL
Intervention: Prognostic index scoring based on personal, tumour, and functional information.
Number of subjects: 4479
Study: 15056067

Group type: EXPERIMENTAL
Intervention: Erbium: YAG Laser cataract extraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cataract surgery
Number of subjects: 0
Study: 11022053

Group type: COMPARATOR
Intervention: Plasma antioxidants (vitamin C, uric acid, vitamins A and E) and antioxidant enzyme activities (SOD and glutathione peroxidase) measured at various time points
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Vitamin A and uric acid plasma levels, erythrocyte SOD activity
Number of subjects: 38
Study: 8540219

Group type: EXPERIMENTAL
Intervention: Denatonium benzoate (DB) at 30 ppm added to ethylene glycol and methanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethylene glycol and methanol without DB
Number of subjects: 0
Study: 2515973

Group type: EXPERIMENTAL
Intervention: 150 micrograms levothyroxine day‐1 (group A)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 400 micrograms iodine day‐1 (group B)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 75 micrograms levothyroxine and 200 micrograms iodine day‐1 (group C)
Number of subjects: 166
Study: 707973

Group type: EXPERIMENTAL
Intervention: Low dose combination type oral contraceptive
Number of subjects: 14

Group type: COMPARATOR
Intervention: d-norgestrel-releasing intrauterine device (d-Ng-IUD)
Number of subjects: 14
Study: 31537812

Group type: EXPERIMENTAL
Intervention: Chemotherapy (n=82)
Number of subjects: 158

Group type: COMPARATOR
Intervention: No chemotherapy (n=76)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ki-67 assessment using method A (cut-off 10%)
Number of subjects: 158
Study: 28750832

Group type: EXPERIMENTAL
Intervention: Working memory training (dual n-back) for six weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Processing speed training (active control)
Number of subjects: 0
Study: 25165041

Group type: EXPERIMENTAL
Intervention: Eltrombopag 100 mg daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 23648244

Group type: EXPERIMENTAL
Intervention: Domestic live attenuated hepatitis A vaccine (Group A)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Domestic inactivated hepatitis A vaccine (Group B)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Imported inactivated hepatitis A vaccine (Group C)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Hepatitis B vaccine (Group D)
Number of subjects: 493
Study: 21645836

Group type: EXPERIMENTAL
Intervention: Tinzaparin (100 IU/kg subcutaneously daily for 90 days) along with usual postoperative care
Number of subjects: 550

Group type: COMPARATOR
Intervention: Usual postoperative care including chemotherapy when indicated
Number of subjects: 550
Study: 19332468

Group type: EXPERIMENTAL
Intervention: Development of new ECG strain
Number of subjects: 7409

Group type: EXPERIMENTAL
Intervention: Regression or persistence of ECG strain
Number of subjects: 7409

Group type: COMPARATOR
Intervention: Absence of strain on both ECGs
Number of subjects: 7409
Study: 16690550

Group type: EXPERIMENTAL
Intervention: Word Reading Test (WRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Word Memory Test (WMT)
Number of subjects: 0
Study: 15492861

Group type: EXPERIMENTAL
Intervention: SPS (600 mg daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11385165

Group type: EXPERIMENTAL
Intervention: Cutting Balloon angioplasty (CBA)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (PTCA)
Number of subjects: 47
Study: 9207819

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ranitidine 150 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7820217

Group type: EXPERIMENTAL
Intervention: Insulin bolus 0.15-0.75 U/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Insulin withdrawal and 3 days of intensive insulin therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Basal pancreatic polypeptide levels
Number of subjects: 60
Study: 3124602

Group type: EXPERIMENTAL
Intervention: Stepwise increase in daily dosage (1 to 4 g/kg) at a steady rate over 24 hours
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Stepwise increase in daily dosage (1 to 4 g/kg) at a steady rate over 16 hours, followed by a rest period of eight hours
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Full dosage (4 g/kg) at a steady rate over 24 hours
Number of subjects: 45
Study: 30956160

Group type: EXPERIMENTAL
Intervention: Single-implant overdentures (IODs)
Number of subjects: 22

Group type: COMPARATOR
Intervention: New complete dentures (CDs)
Number of subjects: 22
Study: 27739230

Group type: EXPERIMENTAL
Intervention: ARC-520 Injection (0.01-4.0 mg/kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 26220024

Group type: EXPERIMENTAL
Intervention: Cocaine users
Number of subjects: 83

Group type: COMPARATOR
Intervention: Non-drug-using healthy males
Number of subjects: 83
Study: 22903391

Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Lurasidone 120 mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 21764706

Group type: EXPERIMENTAL
Intervention: Octreotide (100 µg daily subcutaneous injection for 7 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no medication before surgery)
Number of subjects: 50
Study: 18385744

Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg day(‐1))
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hypertensive patients (without treatment)
Number of subjects: 25
Study: 16495011

Group type: EXPERIMENTAL
Intervention: rTMS of M1
Number of subjects: 20

Group type: COMPARATOR
Intervention: rTMS of S1, preM, and SMA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 14629937

Group type: EXPERIMENTAL
Intervention: Midvastus approach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medial para‐patellar approach
Number of subjects: 30
Study: 11073734

Group type: EXPERIMENTAL
Intervention: 4% tea tree oil nasal ointment and 5% tea tree oil body wash
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% mupirocin nasal ointment and triclosan body wash
Number of subjects: 0
Study: 8762212

Group type: EXPERIMENTAL
Intervention: Combined slow-release verapamil (180 mg daily) and trandolapril (1.6 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atenolol (71 mg daily) and chlortalidone (18 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1315294

Group type: EXPERIMENTAL
Intervention: Six additional cycles of chemotherapy (lomustine, cyclophosphamide, doxorubicin, etoposide)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No additional treatment until relapse (control group)
Number of subjects: 79
Study: 6384489

Group type: EXPERIMENTAL
Intervention: Supportive, problem-solving group intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30718038

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 29544956

Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 39

Group type: COMPARATOR
Intervention: PP-EES
Number of subjects: 39
Study: 27452639

Group type: EXPERIMENTAL
Intervention: Fish oil supplement of n-3 PUFA (720mg 20:5n3 + 480mg 22:6n3/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (1.8g oleic acid/d)
Number of subjects: 40
Study: 24571729

Group type: EXPERIMENTAL
Intervention: Exercise intervention (details not specified)
Number of subjects: 76
Study: 22321325

Group type: EXPERIMENTAL
Intervention: Observational group received comprehensive health education including dietary guidance and psychological support.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group received traditional health education with routine preoperative education.
Number of subjects: 125
Study: 19421067

Group type: EXPERIMENTAL
Intervention: Interactive multimedia‐based tutorials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional, lecture‐based models
Number of subjects: 0
Study: 16882901

Group type: EXPERIMENTAL
Intervention: Plantar fascia-stretching protocol
Number of subjects: 82

Group type: COMPARATOR
Intervention: Achilles tendon-stretching protocol
Number of subjects: 82
Study: 15598475

Group type: EXPERIMENTAL
Intervention: Formoterol 10 microg BID via multidose DPI
Number of subjects: 239

Group type: COMPARATOR
Intervention: Albuterol 180 microg QID via pMDI
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 11398578

Group type: EXPERIMENTAL
Intervention: Hormonal Replacement Therapy (HRT)
Number of subjects: 112
Study: 9252601

Group type: EXPERIMENTAL
Intervention: 2 weeks of postoperative immobilization
Number of subjects: 42

Group type: COMPARATOR
Intervention: 3 weeks of postoperative immobilization
Number of subjects: 42